IGC (IGC Pharma) Moat Score: 3/10 (As of Jun. 28, 2026)


IGC IGC Pharma Inc IGC
29 GF Score
Price $0.26
GF Value $0.24
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Moat Score?

IGC Pharma IGC +0.42% 29 Moat Score is 3 as of Jun. 28, 2026. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,402 Biotechnology companies, IGC Pharma ranks better than 75.46% on this metric.

IGC Pharma has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

IGC Pharma has No Moat: IGC Pharma has some potential in intellectual property with its focus on cannabinoid-based therapies, but lacks market leadership, strong brand, or significant regulatory barriers. Its competitive position is weak and highly dependent on successful drug development.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes IGC Pharma might have No Moat - Very weak/transient advantages.

IGC Pharma  (AMEX:IGC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

IGC Pharma Moat Score Related Terms

IGC vs CRVO, NEUP, CELU: Moat Score Comparison

For the Biotechnology subindustry, IGC Pharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Moat Score distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Moat Score falls into.


IGC
29GF Score
IGC Pharma Inc IGC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
IGC Pharma (IGC) has a Moat Score of 3 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, IGC Pharma ranks #344 out of 1402 companies in the Biotechnology industry, placing it in the top 24.5%.
Is IGC Pharma's Moat Score too high?
IGC Pharma's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. IGC Pharma's value of 3 is 50% above this industry median. Based on the distribution chart, IGC Pharma ranks #344 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Moat Score compare to CRVO and NEUP?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #344 out of 1402 companies for Moat Score. This places IGC Pharma in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. IGC Pharma's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IGC Pharma's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Fairly Valued. The stock's GF Value™ is $0.24, compared to a current price of $0.26 — trading 9.6% above its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For IGC Pharma (IGC), the current Moat Score is 3 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (IGC) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of $0.26 is trading 9.6% above its estimated GF Value™ of $0.24. GuruFocus considers IGC Pharma to be Fairly Valued.

Key valuation signals for IGC:

  • Moat Score: 3
  • GF Value™: $0.24 vs. price of $0.26 (9.6% above fair value)
  • GF Score™: 29/100 with 6 warning signs
  • Industry Position: 50% above the Biotechnology median (#344 of 1402)

No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IGC Pharma Business Description

Other Exchanges IGS1:Germany
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score

Get the complete analysis for IGC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price
$0.24
GF Value